Table 2.

Cox proportional hazards analyses of TACE plus sorafenib versus TACE alone on PFS and OS.

Analysis	HR	95% CI		p-Value
PFS
Unadjusted	0.622	0.459	0.842	0.002
Adjusted	0.651	0.476	0.890	0.007
Propensity score matched *	0.463	0.310	0.693	<0.001
Propensity score matched and adjusted for selected variables †	0.443	0.286	0.687	<0.001
OS
Unadjusted	0.701	0.514	0.955	0.024
Adjusted	0.750	0.543	1.035	0.080
Propensity score matched *	0.583	0.399	0.853	0.005
Propensity score matched and adjusted for selected variables ‡	0.574	0.377	0.872	0.009

HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; OS, overall survival. * Cox proportional hazard models, with robust standard errors that accounted for the clustering of matched pairs. † Adjusted for tumor number, tumor extent, bilirubin, and Child–Pugh score, which were significant in the univariable analysis. ‡ Adjusted for maximal tumor size, tumor number, tumor extent, bilirubin, Child–Pugh score, and AFP, which were significant in the univariable analysis.